Recent Updates
Recently added Catalysts
EDIT

Editas Medicine to Present at Cowen and Company 36th Annual Health Care Conference

Key Takeaway: CAMBRIDGE, Mass., March 01, 2016 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it will present a company overview at the Cowen and Company 36th Annual Health Care Conference on Tuesday, March 8, 2016 at 8:40 a.m. E

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+125%
120-day peak, hindsight
Typical move
5.8%
average across 6 past catalysts
Cash runway
~21 mo
Low dilution risk
Lead asset
EDIT-301
Phase 1 · Transfusion Dependent Beta Thalassemia

Full Press Release Details

CAMBRIDGE, Mass., March 01, 2016 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it will present a company overview at the Cowen and Company 36th Annual Health Care Conference on Tuesday, March 8, 2016 at 8:40 a.m. ET.
A live webcast of the presentation will be available on the Investors & Media section of the Editas website at www.editasmedicine.com. An archived replay will be available for approximately 30 days following the presentation.
About Editas Medicine
Editas Medicine is a leading genome editing company dedicated to treating patients with genetically defined diseases by correcting their disease-causing genes. The company was founded by world leaders in genome editing, and its mission is to translate the promise of genome editing science into a broad class of transformative genomic medicines to benefit the greatest number of patients.
Last updated: Mar 1, 2016